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This article takes up biomedical and public health concerns about the difficulty of 
generalizing or extrapolating measurements of efficacy produced by the method of the 
randomized control trial (RCT) to wider populations. While explanations for the 
difficulty may be deduced from social studies of science that reveal the contingent and 
situated nature of trial findings, new conceptual tools are required to allow for the 
practical value associated with the possibility of their extrapolation. We argue that Alfred 
North Whitehead’s concept of 'abstraction' can provide an alternative appreciation of 
some key aspects of the processes of knowledge-production of RCTs to enable a recasting 
of the problem of generalization. By proposing that generalization depends on relevant 
abstractions, we direct attention to the situated forms of care that this calls for. After 
showing the conceptual difference that the process of abstraction makes for understanding 
and extrapolating the situated nature of a research finding, we offer an interpretation of 
possible forms of care at work in efforts to devise Ebola adaptive trials. The example is 
offered as one possible basis for a reformulation of the logic of generalization.   
        
 




A Careful Biomedicine? Generalization and Abstraction in RCTs  
 





Across the numerous fields of health and medical inquiry and intervention in evidence-
based medicine (EBM), the randomized control trial (RCT) is regarded as the method 
best designed to statistically establish the validity of an intervention and, therefore, to 
address the question of whether it is better than another or better than none, that is, the 
question of equipoise (Freedman, 1987).  It is the capacity of the RCT to suggest causal 
relationships under specified optimal conditions that has gained it pride of place for 
producing evidence of ‘efficacious’ interventions. As Rothwell states: ‘Randomised 
controlled trials (RCTs) and systematic reviews are the most reliable methods of 
determining the effects of treatment’ (2005:82). In order to provide such reliability, 
Rothwell adds, RCTs ‘must be internally valid (ie, design and conduct must keep to a 
minimum the possibility of bias)’ (2005:82). Nonetheless, an extensive array of debate 
ensues about how to overcome the difficulty of extrapolating or generalizing RCT 
evidence to other situations and, in reference to social interventions, whether this can be 
achieved at all (Bonell, 2002; Kippax and Van de Ven, 1998).  
 
Within the field of social studies of medicine, ethnographic studies have shown that the 
difficulty of generalization resides with the presumption that RCT’s produce an objective 
measure of probable causality. Such studies draw attention to the manner in which RCT 
findings are contingent on the many variable conventions and processes that comprise the 
method: for example, modes of standardization such as guidelines and protocols, 
marketing and drug regulation processes, data collection and review techniques 
(Cambrosio, Keating, Schlich and Weisz, 2009; Michael and Rosengarten, 2013; 
Timmermans and Berg, 2003; Will and Moreira, 2010). Thus, by contrast to the premises 
of the RCT to be discussed below, research in social studies of medicine suggests that 
evidence is not achieved simply by the detection of an externalized objective process able 
to transcend the situations in which it is collected (Robinson and Norris, 2001). Rather, 
'evidence' is the outcome of situated practices and processes that labour towards its 
realization. Hence, since all effects are situated, emergent through the specific relational 
dynamics involved in their accomplishment–whether this is due to the situation of the 
RCT, in policy-making, or elsewhere–nothing would immediately warrant that they could 
happen elsewhere.  
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On this basis, and bearing in mind the importance of the RCT to EBM, this article takes 
up concerns about the difficulty of generalizing or extrapolating measurements of 
efficacy produced by the method of the RCT to wider populations and asks: what 
underpins the claim of generalizable evidence? Further, what alternative mode might 
enable findings more relevant to the situated nature of biomedical and other health 
interventions?  To address the latter question, we introduce Alfred North Whitehead's 
concept of 'abstraction' and Maria Puig de la Bellacasa's notion of 'care', followed by a 
discussion of Ebola biomedical adaptive trials. The latter have been selected for the 
manner in which they reflect an increasing interest in research adaptation across 
biomedicine and public health. In this vein, they enable us to show how an engagement 
with the RCT method can be turned to reformulate generalization as a precarious and 
unstable process always dependent on relevant, situated abstractions. As such, adaptive 
trials also enable us to extend our proposition for a ‘careful biomedicine,’ one responsive 
to what is emerging in public health research apart from the reliance on the RCT (see for 
example, Walker and Jacobs, 2002; Valters, Cummings and Nixon, 2016).  
 
The logic of generalization: isolated causal mechanisms and the problem of 
externalized contingencies 
 
Hinging as it is on the minimization of biases that may confound the evidencing of the 
probability of a causal principle, the notion of internal validity within the method of the 
RCT involves the presupposition that an intervention’s causal ability can be isolated and 
contrasted against a predetermined statistically significant outcome (Howick, 2011). By 
implication, this view of causality presupposes what sociologist of science Bruno Latour 
(1988) called a “process of purification”, which selectively establishes distinctions 
between what counts as relevant data and what does not. Most notably, the conventional 
RCT method involves the randomization of human subjects, presumed to be equivalent as 
a ‘population’ within the trial, to either a ‘control’ one or more ‘treatment’ groups.  
Randomization is believed to eliminate ‘bias,’ such that calculations of statistical 
probability of an effect in the ‘treatment’ group/s can be contrasted with the ‘control’ for 
the purpose of generalizing the intervention’s effect. Probability thus enables the 
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induction of causality without, in fact, explaining ‘why something should or should not 
work’ (Timmermans and Berg, 2003:3).   
 
Contrasted with what is understood as 'efficacy’ testing by the RCT, ‘effectiveness’ is the 
degree to which the results can be found in a new situation and, for the most part, 
determined through observation. When effectiveness does not take place in the new 
situation, the reasons for this have traditionally been attributed to impeding external 
contingencies such as: less specialized skill levels of administration of the intervention 
than in that of the RCT; more challenging access and take up modes than in the RCT 
(Singal, Higgins, and Waljee, 2014); patients having co-interfering conditions than those 
in the RCT (Zwarenstein and Treweek, 2009); and, seen from a health programming 
perspective, that the circumstances for intervention ‘change in rapid, complex and 
unpredictable ways’ (Valters, Cummings and Nixon, 2016).  
 
Across the different disciplinary fields seeking to redress what is viewed as a problem of 
translation from efficacy to effectiveness, while relying on the status of RCT for EBM, it 
is possible to identify an array of different strategy proposals. Amongst epidemiologists 
focused on translation to a clinical setting, there are calls for a continuum of trials, 
beginning with an explanatory mode associated with the conventional RCT efficacy 
testing, and followed by what are termed “pragmatic trials” allowing, in their design, for 
consideration of multiple so-called potential external contingencies alongside or post 
RCT efficacy testing (Singal, Higgins and Waljee, 2014:3; Treweek and Zwarenstein, 
2009; Thorpe et al., 2009). Rod et al. (2014), for their part, argue for a need in public 
health intervention to move beyond the question of “what works”, in favour of a more 
nuanced attention to what they call “social effectiveness” of intervention programmes– 
namely, an attention to the creation of shared understandings amongst researchers and 
practitioners, and the ways in which such intervention programmes reconfigure social 
relationships. Others, located within the primary health care and health programme 
implementation, propose a more participatory approach that involves practitioners and 
patients, or researchers and consumers, being able to exercise discrimination in the 
application of efficacy evidence and, in doing so, give consideration to other forms of 
knowledge (Greenhalgh, Howick and Maskrey, 2014; Walker and Jacobs, 2002; White, 
2001). 
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Despite the somewhat different approaches for overcoming the difficulty of 
generalization set out above, what they share is the need for a compromise between an 
ideal of generalization and the situated nature of effects as made evident by social studies 
of medicine. It is this very notion of compromise that arguably also animates the 
distinction between ‘efficacy’ and ‘effectiveness’ findings. Whereas efficacy is assumed 
to be an achievement of RCT ‘optimal’ conditions for testing and thus likely to provide 
the most rigorous scientific evidence, effectiveness is understood as a situated challenge, 
susceptible to difficulties posed by the contingencies of each situation, and thus holding 
weaker epistemic and scientific potential.    
 
Alongside these approaches, the practice of ‘adaptation’ is acquiring increasing interest 
across both medicine and public health for how it may enable more relevant evidence and, 
where possible, reduce the time it takes to achieve a desired result (Brown et al., 2009; 
Chow and Chang, 2008; Victora, Habicht and Bryce, 2004). To be sure, the array of 
adaptive types across these two overlapping fields is complex and it is beyond the scope 
of this article to enter into the ‘whys’ and ‘wherefores’ for their various differences. Here 
it will suffice to say that we are interested in approaches that involve ‘adaptation’ in situ. 
That is, where data is not only accumulated during the trial but is fed back into shaping 
aspects of the research in process (Brown et al., 2009). The reasons for our specific focus 
on adaptation in situ resonate in some crucial ways with the ongoing learning processes 
proposed by Valters, Cummings and Nixon (2016) in health implementation and, noted 
by Montgomery (2017:234), as a central feature of ‘adaptive’ biomedical trials.    
 
Yet, despite the practical departure of ‘adaptive’ trial designs from pre-set ‘optimal’ 
conditions, by incorporating into the process of learning, data generated during the life of 
the trial, the presupposition of an isolated agent open for extrapolation to a new situation 
still forms part of their context of justification. In a comprehensive review of the pros and 
cons of adaptive trials versus the conventional RCT, Brown et al. (2009) acknowledge the 
rigidity of the latter method but nevertheless give expression to a prevailing view that the 
model of the adaptive trial is unable to provide answers to questions about probability for 
the purpose of generalization. As such, this presupposition is seen to weaken the 
epistemic importance of adaptive trials for EBM and public health policy. As 
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Montgomery (2017:246) notes: ‘The more decisions or adaptations that are envisaged, the 
more difficult it is to know how the design will perform under different scenarios.’  
 
Here we challenge the aforementioned devaluation of adaptive trials, and do so by 
problematizing the very presupposition of an isolated agent that underpins it. Labouring 
towards the idea of a 'careful biomedicine', we provide a cautious revaluation of adaptive 
trials that is appreciative of how the situated nature of an effect alters current assumptions 
about generalization. To do so, we first need to address what we have sought to highlight 
as a persistent paradox in the logic of the RCT and EBM, whereby contingencies are 
simultaneously acknowledged as central to the effects of an actual intervention, and 
eschewed from its own criteria of explanatory validity. Thus, in what follows we propose 
a different conceptual approach. An approach that is able to discern between the 
pragmatic value of the possibility of extrapolation apparent in the shift to adaptive trails, 
and the otherwise problematic consequences of the logic of generalization currently 
employed in EBM. In order to attempt this, we turn to the work of philosopher Alfred 
North Whitehead, his historical account of the development of modern mechanistic 
science, and his concept of ‘abstraction.’ 
 
The concept of abstraction and the history of science 
 
In his heterodox history of modern science, Whitehead (1967) traces the development of a 
mechanistic logic of causality with its concept of an ideally isolated system to Galileo. By 
setting up a purified experimental system that could single out a number of critical 
variables, Galileo was able to assert that the measure of speed produced within such a 
system was relevant to the behaviour of motion of physical bodies. According to 
Whitehead, the achievement of the isolated system, which involved the technical 
construction of an experimental apparatus able to exclude other factors, was a major 
technical accomplishment in abstraction, that is, the achievement of a partial taking from 
a whole. It is important to stress that, for Whitehead, abstraction is not just an elective 
mental operation but designates a process that is as crucial as it is ubiquitous, performed 
by all organisms. As such, it can neither be avoided nor overcome. Abstraction takes 
place at all levels of existence: a plant extracts water and minerals from the soil in which 
it situated and so, too, do thoughts extract from their situations. Indeed, when ‘it abstracts, 
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thought is […] exhibiting itself as an element in nature’ (Whitehead, 1927:26), and 
creatively so. This process, moreover, is fundamental, such that ‘we cannot think without 
abstractions’ (Whitehead, 1967:73). But, while ubiquitous across nature, the process of 
abstraction is itself always situated, concerning each and every situation that different 
organisms help compose in their own specific ways: ´[abstraction] occurs in a specific 
field or with regard to a specific problem; this is what provides it with both its purpose 
and its effectivity’ (Halewood, 2011:6).  
 
The Galilean event was an achievement of abstraction in the sense that Galileo succeeded 
in setting up a system of measurement and testing whose limited variables could be 
functionally isolated from the wider set of relationships that made up its environment, 
thus giving way to the development of experimental methodologies across the modern 
sciences. The effects of this event upon scientific thought have been far-reaching. Taking 
up the way in which physics has, since the Galilean event, come to predominate and 
model much of the thinking of the sciences, Whitehead expressed the concern –one that 
we are seeking to make resonate with the methods of the RCT and its evidence for 
generalization– that this event has since become the basis for a scientific materialism 
according to which nature is understood ‘in terms of stuff, of matter […] which has the 
property of simple location in space and time´ (Whitehead, 1967:49). In other words, 
Galileo's achievement of a functionally isolated system was turned into an entire 
scientific worldview of ontologically isolated things, with the effect of becoming one of 
‘the most natural ideas for the human mind [such that] without these ways of thinking we 
[moderns] could not get our ideas straight for daily use’ (Whitehead, 1967:52). What was 
the achievement of a specific experiment in physics, has acquired the status of a doctrine, 
of an ‘orthodox creed’ (Whitehead, 1967:51), and is now the cardinal methodological aim 
of efficacy testing in RCTs: the doctrine of simple location. According to the doctrine of 
simple location, nature is composed of isolated bits of matter ‘that can be said to be here 
in space and here in time, or here in space-time, in a perfectly definite sense which does 
not require for its explanation any reference to other regions of space-time’ (Whitehead, 
1967:49).  
 
Despite its ubiquitous presence in modern scientific thinking, one of the problems with 
this doctrine –as noted above in reference to the efficacy/effectiveness distinction– is that 
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to suppose that things exist in separation from each other makes it difficult to account for 
‘how one such substance can form a component in the make-up of another such substance’ 
(Whitehead, 1927:26), that is, how one thing can be present in, and affect, another. For 
Whitehead, there is therefore a fundamental paradox at the heart of a science that 
espouses the assumption of simple location and employs a logic of induction to infer 
relations of causality, because 
 
if in the location of configurations of matter throughout a stretch of time there is 
no inherent reference to any other times, past or future, it immediately follows that 
nature within any period does not refer to nature at any other period. Accordingly, 
induction is not based on anything which can be observed as inherent in nature. 
(Whitehead, 1967:51) 
 
As a consequence of this history of scientific thinking, abstractions, which emerge out of 
the situated deployment of a ‘method of suppressing what appear to be irrelevant details,’ 
come to be deemed more real than –and thus replace– the complex concreteness of the 
situation from which it was abstracted. In this way, what was once discarded as irrelevant 
becomes simply invisible. As Whitehead puts it (1967:50), when an abstraction is 
confused with the concrete realities from which it draws, ‘[t]here is an error […] of 
mistaking the abstract for the concrete. It is an example of what I will call the “Fallacy of 
Misplaced Concreteness”.’ There is an error because, as intimated above, those forms of 
knowledge that postulate clear and distinct things and qualities as simply located objects 
can only do so by enforcing upon every situation they study their own judgment of 
relevance, implicit or explicit in their own modes of abstraction. It is the abstraction that 
allows them to suppress what they consider to be irrelevant detail. Nothing guarantees, 
however, that what certain modes of abstraction consider relevant is indeed relevant to 
producing knowledge of, or intervening in, the situation from which they are abstracting 
(Savransky, 2016).  
 
We can now see how biomedical and public health engagement with the question of 
generalization of RCT evidence stems from the event of an abstraction taken for actual, 
ontological, fact. And to the extent that this presupposes the doctrine of simple location 
not as an abstraction but as a fact of nature, it undermines the potential of the varying 
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attempts outlined above to rethink the problematic of generalization. Our aim, however, is 
not to denounce efforts to enable generalizations. What we suggest, by contrast, is that 
Whitehead’s treatment of the concept of abstraction does more than offer a diagnosis of 
the history of biomedical culture. It provides an alternative way of evaluating, and of 
responding to, what is expressed in such attempts.   
 
It follows from our excursus into Whitehead’s concept of abstraction that, while all forms 
of knowledge create abstractions that simplify the complexity of concrete fact, no method 
of knowledge-production can constitute a ‘gold-standard’ as now presumed of the method 
of the RCT (Bonell, 2002; Timmermans and Berg, 2003). That is to say, no method of 
inquiry can, as a matter of principle, produce abstractions that are relevant to all situations. 
But this does not preclude the possibility that an abstraction may be relevant to many 
situations. As Whitehead (1967: 50) humorously acknowledged of those who turned the 
abstraction of a functionally isolated system into an ontological doctrine of simple 
location, ‘the creed justified itself by the pragmatic test. It worked.’  But, as many public 
health practitioners working to implement an intervention will be aware, the adjustment 
of any efficacy measures to so-called external contingencies always involves a situated 
test. It may work, it may even work frequently, but only the doctrine of simple location 
warrants that it should always work as a matter of principle. Put differently, abstractions 
are situated in the sense that they emerge as a response to a specific problem. They can 
indeed prove to be relevant in many situations. But to abstract is not to generalize. To the 
extent that the notion of generalization stems from the abstraction of an isolated system, 
Isabelle Stengers (2008:96) rightly remarks that abstractions, for Whitehead, ‘are not 
generalizations.’ Whereas generalizations are always concerned with the problem of 
representation, and their aim is that of issuing probabilistically accurate, objective, or true 
statements of an independent world, the function of abstractions is 'not to produce new 
definitions of what we consensually perceive and name, but to induce empirically felt 
variations in the way our experience matters’ (Stengers 2008: 96). 
 
Indeed, abstractions can, but need not be, statements at all, and they are not governed by 
the requirements of representation. The example of the abstracting plant mentioned above 
is illustrative: a plant abstracts water and minerals from the soil, but of course, it needs 
not produce a representation of them in order to experience the variations that these 
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abstracted elements induce in its experience. At the human end of the spectrum, Stengers 
(2008:96) illustrates this feature of abstraction by attending to the way in which the 
abstraction of a circle operates in mathematical thought. As far as mathematics is 
concerned, the circle need not refer to any actual circle. The function of the circle, 
moreover, is not to instruct mathematicians on the common properties of all actual circles 
–were such a thing to exist– but to ‘lure mathematicians into adventures which produce 
new aspects of what it means to be a circle into a mathematical mode of existence.’ 
 
The task of abstractions, therefore, is not to be ‘true’, but to be relevant (Savransky, 2016). 
Their aim is to ‘act as “lures”, luring attention towards “something that matters”, 
vectorising concrete experience’ (Stengers, 2008: 95). Because their task is to be relevant 
to the concrete situations in which they operate, the relevant scope of an abstraction can 
never be guaranteed. Despite the premise of EBM, according to which the production of 
'best evidence' hinges on the particular method used to collect it, to attend to the processes 
of abstraction undertaken by method-driven research is to trouble expectations of the 
replication of results in a different situation, particularly the expectation that such an 
event of replication can be determined methodologically, as a matter of principle. Instead, 
relating to abstractions is always a pragmatic challenge, a question of the relevance of a 
specific abstraction to a particular situation. This pragmatic challenge, we argue, demands 
that one learns to care for the ways in which abstractions operate in concrete situations.    
 
Caring for Abstractions 
 
To speak of a care of abstractions involves, as Maria Puig de la Bellacasa (2011:100) 
proposes, a ‘transformative ethos’ that introduces the question of ‘“how to care” in each 
situation’. But here the notion of care does not evoke the connotations of a form of warm, 
pleasant affection, and it cannot be reduced to the clinical side of a medical practice –or 
other practices involved in the implementation of EBM– that would have rigorous 
scientific knowledge as their counterpart. In Puig de la Bellacasa's ethico-political 
rendering of the term, care is an attentive response to the systematic neglect and 
undervaluing of some issues at the expense of others. Indeed, for Puig de la Bellacasa 
(2017: 15) care thus involves an entire ‘politics of knowledge at the heart of 
technoscientific, naturecultural world.’  
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The notion of ‘care’ is thus a particularly apposite notion to explore the uses of 
abstractions: to interrogate what forms of neglect they involve, and the extent to which 
their criteria of relevance are adequate to the situations in which they operate.  It is not 
only a matter of detecting what is and is not included but also about caring for, as Puig de 
la Bellacasa (2011: 96) states: ‘what this thing could become’ within current constraints. 
To care for abstractions is thus to become attentive to, and vigilant of, the particular 
modes of abstraction and the kinds of dynamic connections and disconnections that may 
be possible to cultivate with the situation of concern. In this sense, the notion of care does 
not simply provide an analytical framework through which to interrogate techno-scientific 
practices from without, but enables a different sort of interrogation, more generative and 
generous, with which the practices of biomedicine may be directly concerned. This is the 
question of how a certain research methodology may continously adjust its modes of 
abstraction and thus seek to become more careful.  
 
In the next section we attend to the efforts within biomedicine that, by their design, 
displace the efficacy and effectiveness distinction of the RCT. We suggest that a nascent 
orientation to the use of abstractions and away from the concern with ‘contingencies’, 
posited as external by prevailing biomedical and public health thinking, can be appraised 
in the practice of ‘adaptive biomedical trials’ despite their purported adherence to a mode 
of causality that raises concern about generalization as a logical consequence of its 
methodology (Brown et al., 2009).  
 
Abstraction in Adaptive RCTs  
 
In what follows, our aim is to constructively contribute a different understanding of the 
nature of evidence and what it means to extrapolate a situated effect when caring for 
abstractions. This involves dramatizing a practice, albeit unacknowledged by biomedicine, 
of caring for abstractions as illustrated in the shift to ‘adaptive trials’, namely, clinical 
trials which, in different ways, modify some of their parameters and protocols in view of 
their ongoing outcomes. To do so, we draw on the constructive characterisation by 
statistician Steve Kanters (2014) as fruitful responses to the evolving demands of the 
Ebola outbreak during 2014 – 2016. It is the combination of the successful development 
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of an alternative mode of abstraction evinced in one Ebola vaccine trial, together with an 
emerging revaluation of its evidence-value in the discourse of some statisticians, which 
initially enabled us to grasp adaptive trials’ practical value for reformulating the 
efficacy/effectiveness distinction now underpinning the notion of ‘best evidence’.  To be 
sure, there are many other adaptive approaches that we might have selected– notably, 
those concerned with non-biomedical interventions (see for example, Brown et al., 2009; 
Victora, Habicht and Bryce, 2004). But given that it is a certain logic of scientific 
evidence which gives weight to the RCT method, and that central to our proposition for a 
careful biomedicine is to rethink the presuppositions of generalization, we believe a 
conceptually stronger case for our proposition may be achieved by focusing on adaptation 
in biomedicine. That said, it is important to note that our discussion below is not intended 
as a comprehensive examination of the socio-technical complexities of the adaptive trial, 
and it does not seek to mobilize the cases we discuss to make evidential appeals of its 
own. Such an aim, although urgent and important, is beyond our current scope.  
 
In what follows, we pursue a speculative and more modest endeavour, of seeking to 
disclose, in some of the methodological and evaluative dimensions of three adaptive trials, 
gestures that may be generative of a more careful way of engaging the situated processes 
of abstraction and generalization involved. Indeed, our efforts are themselves abstractive 
in their own way, devised to vectorize the possibility of a different mode of engagement 
with biomedical evidence in public health, one whose full realization will no doubt 
require further, in-depth, situated attention to the complexities of each trial in question. 
 
In his endorsing statements, Kanters provides only a sketch of two adaptive trials: (1) 
TKM-Ebola later not found to reach its target effect (Dunning et al., 2016), and (2) 
Zmapp, halted due to the constraints of what emerged as a declining epidemic (The 
Prevail Writing Group, 2016). Nevertheless, his argument is noteworthy, for it is crucially 
concerned with aligning the need to ‘acquire critical scientific knowledge as well as help 
patients in dire need of treatment.’ The need to do so, framed according to bioethics, was 
expressed in response to the view that the conventional RCT is the most ethical mode of 
research as it involves pre-safety testing and, as we have noted above, it is also regarded 
as the most epistemically robust method to achieve generalizable claims due to the role of 
randomization in statistical comparison. However, for Kanters and many others reviewing 
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the various adaptive trials proposed and undertaken during the epidemic, the strict nature 
of the conventional RCT is precisely its limitation (see Whitehead et al., 2016; Yin, Lam, 
and Shi, 2017). As Kanters (2014) states, the conventional RCT relies on ‘pre-planned 
and assumed knowledge’ which limits what can be learnt and achieved during its 
undertaking– a concern made most pertinent in response to the urgency of Ebola. 
Emphasizing what is most problematic about the conventional RCT when seeking a novel 
intervention, he goes on to say:  
 
In reality … many trial designs would be altered if much of the knowledge accrued 
over the course of the trial were known beforehand. By the time we realise that 
trials should have been changed, or adapted, the strict rules of standard clinical 
trials often do not permit protocol change.   
 
Hence, Kanters suggests, adaptation was required not because it would generally provide 
a better RCT design or more objective and generalizable measures, but above all, because 
of the need to produce knowledge and biomedical technologies in a situation where 
ongoing learning was urgently required.  His description of the process of adaptation 
emphasizes the monitoring of effects during the trial, and adapting it within the research 
undertaking, that is, in-situ. In place of imposing on its test-population a criterion of 
relevance fully determined in advance, hypothesizing a causal mechanism and 
methodologically establishing whether or not it has a probabilistic beneficial or harmful 
effect to determine the trial result, the TKM-Ebola and Zmapp trial designs meant that 
their results would be contingent on relevant, ongoing adjustments to the demands of the 
situation. Because of the potential risk of adverse reactions to a novel intervention, the 
TKM intervention was introduced into the bloodstream over a minimum two-hour period, 
during which clinical monitoring for reactions took place. Moreover, given the constraints 
on providing care in a complex, poorly equipped setting of the West African epidemic, 
the trial’s lead physician decided on a daily basis how many new participants could be 
included (Dunning et al., 2016). By contrast, the ZMapp trial was designed to test a 
complex set of interventions and used a process of randomization that involved a 
response-adaptation mode, shifting patients to a treatment arm as the trail progressed. It 
also included close monitoring of a dosing pattern in-situ (Kirchoff and Pierson, 2017). 
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While on paper the trials did not ostensibly depart from seeking to identify a causal 
mechanism, they (like other adaptive trials) nevertheless could be said to have developed 
a mode of abstraction that was more open, and more responsive, to actively look for data 
that could lure biomedical practices to ‘something that matters.’ In short, the rapidly 
shifting and expanding nature of the situation was prioritized over the usual requirements 
of the methodological gold-standard, with a view to taking care to abstract from the 
situation in ways that would be relevant and responsive to its evolving and rapidly 
changing character. Indeed, the situation shifted so rapidly that, although both trials did 
generate positive results, neither were able to achieve a statistically significant result 
before discontinuing in the face of the decline of the epidemic.      
 
Writing without the knowledge of the outcomes of the two trials, Kanters (2014) 
expressed the following qualification and justification for his endorsement of their design:    
 
The upcoming Ebola trials will be marred with unknowns that are required to 
conduct standard trials. These include uncertainties about the interventions, such 
as efficacy, dosage, co-interventions, and adverse events, and uncertainties about 
the population as the epidemic continues to cause societal and economic turmoil.  
  
To be sure, as we noted above, a version of isolationism pertaining to the mechanistic 
logic of causality remained present in the above cited Ebola adaptive trials, such that the 
intervention was still conceived as the causal feature of the sought effect. But unlike the 
conventional/non-adaptive RCT, this was a functional isolation of a causal factor, devised 
and continuously adjusted in-situ for the purposes of discerning something that matters. 
In other words, the question of relevance, of what does indeed matter in a particular 
situation, was not completely determined by method but retained a degree of openness. 
Indeed, it became part of the very research question, allowing for a careful responsiveness 
to the situation in the ongoing development of the trial’s abstractions.  
 
To be sure, this does not preclude successful adaptive trial findings being taken to refer to 
a generalizable simple location. Nothing in Kanter’s proposal for adaptation or, adaptive 
trials more generally, prevents the findings from later becoming subject to the logic that 
what works here will work somewhere else. But this should not dissuade us from 
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entertaining the shift to adaptation as a vector for extending our thinking on the 
possibilities afforded by the conventional RCT. Despite other conceptual limitations and 
socio-technical complexities, we suggest that the very shift to adaptation in-situ in the 
face of a public health emergency makes the importance of taking care of our abstractions 
resonate.  
 
We turn now to ‘Ebola ça suffit!’, a trial conducted in Guinea to produce a vaccine 
against Ebola and described by its sponsor, the World Health Organisation, as using a 
phased-rollout RCT method (Pulliam, Bellan, Gambhir, Meyers and Dushoff, 2015). In 
brief, a laboratory developed vaccine was put to the test through a ring design tailored to 
respond to what had become a diminishing number of Ebola cases as the pattern of the 
epidemic, itself, shifted to small outbreaks: when Ebola flared up in a village, researchers 
vaccinated all the contacts of the sick person who were willing – the family, friends and 
neighbours – as well as their immediate contacts.  The cluster outbreaks were assigned to 
either receive the vaccine immediately or three weeks after Ebola was confirmed. The 
process of assignment was not done according to the usual process of randomization, but 
by prioritizing vaccination of clusters experiencing high infection and, according to 
Pulliam et al. (2015:1134), conferring ‘the highest likelihood of benefit to those at highest 
risk, thereby reducing the total risk to trial participants relative to a non-risk prioritized 
design.’ Among the 2,014 people vaccinated immediately, there were no cases of Ebola 
from 10 days after vaccination – allowing time for immunity to develop and providing a 
markedly different pattern to that observed in situations where no such intervention had 
been possible. There were 16 cases of Ebola infection out of 2,380 in the clusters with 
delayed vaccination (Krause, 2015).   
 
No doubt, some would claim that the success of ‘Ebola ça suffit!’ can be explained as due 
to the particular nature of the intervention, that is, its situated requirement involving one 
injection to the arm tested in-situ in villages rather than a more complex intervention and 
varying set of circumstances. And, as is the case with any intervention, the long-term 
effects of the vaccine remain unknown. Notably, its duration of protection is yet to be 
observed. But if we entertain the possibility that the research design and intervention may 
have so far proven relevant, we may appreciate how the usual contrast between RCT 
control (efficacy) and real world (effectiveness) conditions loses its hold. In this 
A Careful Biomedicine? Generalization and Abstraction in RCTs  
 
   
 
16 
particular case, it was replaced by a staged delivery process to vectorize an abstraction in 
order to alter an ongoing course of deadly events of infection through exposure to the 
body fluids of an infected individual (Beeching, Fenech, and Houlihan, 2014).   
 
In attending to the use of abstractions, it is necessary to remember that our discussion of 
the successful Ebola trial should not be taken to suggest that the staged design is 
necessarily appropriate to other situations. Unlike the dominant logic of generalization, a 
pre-fixed form of caring for abstractions can never become crystalized in the protocols of 
a general methodology. Hence, it is of import here because it was the situation itself, the 
interaction between the trial and the population with which it was concerned, that was 
relied on to achieve the possibility of a successful vaccine. This certainly poses a 
significant contrast to the conventional notion of ‘efficacy’ which, with its emphasis on 
‘internal validity’ as an achievement of pre-fixed controlled conditions, suggests that for 
an effect to be proven efficacious it would need to obtain in spite of the situation that is 
concerned with its success. By contrast, what we are seeking to make visible is that the 
success of the adaptive ‘Ebola ça suffit!’ trial depended on the careful crafting of a 
relevant abstraction, where a partial knowledge of the processes of viral, body and 
vaccine was synthesized to achieve a concrete effect.       
 
While the RCT provides a method for generalizable knowledge –or would claim to do so 
in principle–caring for abstractions demands that one learns how to come to know a 
situation depending on what the latter itself demands. Thus, it can be argued that shifts 
toward adaptation offer an empirical gesture beyond that of the prevailing logic of 
generalization. Although adaptation of the RCT is not new (Montgomery, 2017), what we 
have sought to disclose is a way of interpreting the differences that adaptive trials might 
make, and the potentialities they may yield. The adaptive mode gestures towards a 
commitment to take care of how an abstraction may operate in relation to those with 
whom it is tested, and in relation to those that put it to the test, without presuming to fully 
know in advance how this should come about.  
 
As such, although it inevitably proceeds from a pre-determined protocol for adaptation, 
the protocol itself does not entirely dictate what would count as relevant and what could 
be discarded as irrelevant detail. Instead it gives recognition to the need for a careful 
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attention to and discernment of what becomes relevant in the course of its own unfolding. 
Doubtless, as Montgomery (2017:236) has argued, adaptive trials still involve forms of 
neglect of the radically unpredictable. But it is also apparent to us that they make the idea 
of a careful biomedicine possible: a kind of biomedical research for which no 
contradiction between rigorous scientific evidence and situated relevance exists, a 
possible biomedicine for which 'the best' evidence for medical practice and public health 
policy is evidence produced with care. In sum, adaptation is conceived in a manner that 
offered the possibility for the tested intervention to become efficacious at the same time 
as it became effective (on similar designs for other conditions see, for example, Chow and 




The work of abstraction suggests that stabilities—the achievement of an effect in and 
across bodies for a period of time as may be observed in EBM—are always partial and 
dynamic achievements rather than mere givens. By adopting this view, there is the 
possibility of associating with the question of biomedical and other health interventions a 
form of inquiry that would neither dismiss outright the possibility that abstractions can 
work in many situations, nor attempt to abstract a claim to efficacy at all costs. This is 
what we have tentatively called a careful biomedicine: one for which ‘the best’ evidence 
for medical practice and public health policy is evidence produced with care.   
 
Caring for abstractions involves taking into account that the challenge of relevance that 
research abstractions face can never be dispelled once and for all, by the sort of 
methodological principles exemplified by the RCT with its notion of 'optimal conditions.' 
When research and policy is underpinned by a presumption of isolated causality, it is thus 
not sufficient to presume that the problem of generalization resides elsewhere with 
externalized contingencies. To put this a little differently, if we can never be sure to 
include all the elements of a situation, it is only by attending to the work of abstraction in 
the achievement of an effect that a careful biomedicine and health intervention become 
possible. Imagining a careful biomedicine, we suggest, allows for the possibility of an 
intervention attuned to the situated nature of its claims, while guarding against the fallacy 
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of presupposing that the abstraction of efficacy can, in and of itself, become an effective 
generalization. 
 
In this way, the idea of a “careful biomedicine” perhaps provides an opportunity for 
reimagining a different sort of relation between the biomedical sciences and critical 
public health research and intervention. Rather than stop at a general critique of RCTs by 
highlighting the often problematic nature of its evidential claims, our proposition of a 
careful biomedicine suggests that the critical health field, with its persistent practices of 
learning to pay attention to what biomedical modes of abstraction neglect, has crucial 
lessons to offer to biomedicine itself. Ones that not only emphasize the latter’s limitations 
but can also proffer alternative propositions for its transformation. As such, it turns the 
tables, so to speak, on the manner in which biomedical evidence is evaluated. Rather than 
depend on the internal validity of the methodological rigour of the RCT, the notion of a 
careful biomedicine places relevance as the situated test of any intervention, and it 
emphasizes that relevance cannot be achieved without an ongoing process of learning, on 
each occasion, how to craft abstractions that may induce felt variations in the way our 
experience matters.  
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